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Background: Chronic Fatigue Syndrome is a debilitating disorder with an unknown aetiology but suspected
multifactorial origins. Common “triggers” include severe viral infections and emotional stress. Recent studies have
also found evidence of immune dysfunction and elevated inflammatory cytokines in CFS patients, but there has
been considerable variation in the outcome measures and magnitude of these studies. Currently, there is no cure
for CFS but treatments include rest, specialist medical care, cognitive behavioural therapy, and graded (self-paced)
exercise. To date, several studies have examined the efficacy of graded exercise with or without Cognitive
Behavioural Therapy, with some success for patients. However, improvements in functional capacity have not
necessarily correlated with improvements in immune function, fatigue or other symptoms. This 12-week pilot trial
compares graded and intermittent exercise to normal care, measuring physiological outcomes, fatigue levels,
immune function and wellness.
Methods/design: 90 patients aged between 16 to 60 years, who meet the diagnostic criteria for CFS and have
been diagnosed by their medical practitioner, will be randomly recruited into groups consisting of Intermittent
exercise, Graded exercise and usual care (Control). The outcomes will be measured pre-study (Week 0) and post-
study (Week 13). Primary outcomes are VO2peak, anaerobic threshold, peak power, levels of fatigue, immune cell
(CD3+CD4+, CD3+CD8+, CD19+, CD 16+CD56+) concentrations and activation. Secondary outcomes include onset of
secondary CFS symptoms (e.g. fever, swollen lymph nodes), wellness, mood and sleep patterns. Primary analysis will
be based on intention to treat using logistic regression models to compare treatments. Quantitative data will be
analysed using repeated measures ANOVA with a linear model, and Cohen’s effect size. Qualitative data such as
participants’ responses (e.g. changes in mood and other reactions) following the exercise modalities will be read
and sections demarcated. A code will be applied to each segment. A prevalence of codes will be considered
thematically.
Discussion: The results of the trial will provide information about the efficacy of intermittent and graded exercise
compared to usual care (rest and lifestyle recommendations), contributing to the evidence for best-practice CFS
management.
Trial registration: Australia and New Zealand Clinical Trials Registry ACTRN12612001241820.
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Currently there is no clear aetiology associated with
Chronic Fatigue Syndrome (also known as Myalgic
Encephalitis). The syndrome is characterised by persistent,
disabling and/or recurring fatigue, not alleviated by rest,
and with other symptoms such as muscle weakness and
pain, swollen lymph nodes and fever, poor concentration
and reduced quality of life [1,2]. A medical diagnosis is
made when three of the following criteria from the Centre
for Disease Control and Prevention’s modified case defin-
ition of CFS, have been met [3]:
(1)The individual has had severe chronic fatigue for 6
or more consecutive months and the fatigue is not
due to ongoing exertion or other medical conditions
associated with fatigue (these other conditions need
to be ruled out by a doctor after diagnostic tests
have been conducted).
(2)The fatigue significantly interferes with daily
activities and work.
(3)The individual concurrently has 4 or more of the
following 8 symptoms: post-exertion malaise
lasting more than 24 hours; unrefreshing sleep;
significant impairment of short-term memory or
concentration; muscle pain; pain in the joints
without swelling or redness; headaches of a new
type, pattern, or severity; tender lymph nodes in
the neck or armpit; a sore throat that is frequent
or recurring.
These symptoms should have persisted or recurred
during six or more consecutive months of illness and
they cannot have pre-dated the fatigue.
CFS is often triggered by a severe viral infection, such as
Epstein Barr virus [4]. There is also increasing evidence to
suggest that CFS is also associated with immune system
dysfunction, such as increased inflammatory cytokines
and reduced lymphocyte activation [4-7]. CFS can cause
severe interruptions to education or employment for pa-
tients, and the physical inactivity associated with the syn-
drome may increase the risk of other chronic conditions
such as cardiac disease, metabolic conditions and cancer.
Earlier studies found that the majority of individuals with
CFS have slight to substantial improvement within 1.5 - 4
years with less than 10% reporting complete recovery
[8,9]. Approximately 20-50% of adults with CFS demon-
strate some improvement in the condition, although only
6% returned to levels of normal function [10,11]. Rehabili-
tation is usually slow with symptoms described as fluctuat-
ing. Approximately 10% of individuals with CFS may
improve for periods of at least a year, with a proportion re-
lapsing intermittently [10,11]. Most patients relate that
they never return to their pre-morbid level of health
[11,12]. After a period of rest, some individuals may returnto work but usually with limited working hours. It is ap-
parent that the combination of tiredness, poor memory
and difficulties with concentration are reflected in the
changes to their productivity.
CFS patients are often advised to remain as active as
possible but patients usually show a range of physiological
responses to exercise indicative of fatigue and decon-
ditioning. Such responses include reduced exercise cap-
acity, early onset of anaerobic threshold, increased lactate
responses during incremental exercise, increased heart
rate responses, and also anomalies within perception of
their physical effort such as higher rates of perceived exer-
tion compared to controls [2,13,14]. Hypothalamic, mito-
chondrial and sympathetic dysfunction may also be
implicated in exercise and fatigue responses in CFS pa-
tients [3,15,16].
Strategies to manage CFS include pharmacology, phys-
ical activity where appropriate (for example graded exer-
cise (GE) and pacing), and psychological approaches
such as cognitive behavioural therapy (CBT) which seek
to modify behaviour, beliefs and coping strategies.
[17-20]. Current best practice for the physical training of
CFS patients involves GE sessions where the patient ex-
ercises at a well-tolerated constant rate or load (steady
state), and the duration of the exercise session is grad-
ually increased over time [2,18-20]. CBT is usually com-
bined with exercise management [18,20].
Evidence of the efficacy of GE, CBT, pacing and other
prescriptions of physical activity has been mixed. Some
CFS patients still report symptom exacerbation and muscle
pain with GE, and consequently are less likely to be physic-
ally active [21,22]. Yet other studies have reported that aer-
obic and resistance exercise improves aerobic capacity and
strength [13], fatigue [17], profile of mood states and in-
flammatory cytokines [14,17,21,23-26].
Intermittent training, where intervals of exercise are al-
ternated with intervals of rest or very low intensity exer-
cise, has been used with cardiac [27], pulmonary [28,29],
cancer [30] and older clients who are very deconditioned
[31]. Clapp et al. (1999) reported that an acute session of
intermittent exercise for 30 minutes did not exacerbate
CFS symptoms immediately post-exercise, or for up to 7
days post exercise [32]. In CFS patients, intermittent train-
ing may increase exercise tolerance by decreasing per-
ceived exertion, and delaying the onset of fatigue and
muscle pain, whilst still providing the same total amount
of physical activity as GE. Patients may find it easier to ad-
here to an intermittent exercise programme if their symp-
toms are not exacerbated, and therefore may improve
their health.
Study hypotheses and aims: the primary aim of the
trial is to investigate the efficacy of 12 weeks of intermit-
tent or graded exercise on aerobic capacity, fatigue, im-
mune function and wellness in CFS patients compared
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about physical activity). We hypothesise that:
1) Both exercise interventions will improve exercise
tolerance, aerobic capacity and wellness compared to
the control condition, and
2) IE will result in greater exercise tolerance, less fatigue
and other symptoms, improved immune function and
better exercise adherence compared to GE.
Methods
Design
This study is a randomised controlled trial that will
compare the outcomes of a 12-week intermittent cycling
exercise program to a graded exercise cycling program
and standard care (rest and lifestyle advice). The primary
outcomes of the study are aerobic capacity (VO2peak),
perceived exertion, fatigue, muscle pain, immune cell
counts, lymphocyte (CD4+, CD8+, CD19+, CD16+56+)
concentrations and function. Secondary outcomes are
wellness indices and physiological adaptations to exer-
cise (changes in heart rate, heart rate variability, blood
pressure, body composition, anaerobic threshold) and
measures of presence, severity and type of fatigue (men-
tal and physical). Southern Cross University Research
Ethics Committee has approved all study procedures
(HREC ECN-13-066).
Sample size and power calculation
A previous exercise intervention study provided VO2peak
data from a CFS sedentary, age-matched cohort (16.2±1.3 yr)
[18]. This data has been used to compute statistical power
a priori using the non-commercial statistical power ana-
lysis program G*Power. The control group is expected to
experience no change in the aerobic capacity after 12-
weeks while the intervention groups are expected to in-
crease this measure following the exercise interventions.
Setting an alpha level of 0.05, approximately 75 partici-
pants (25 per group) will provide 82% power to detect a
statistically significant difference between groups. Recruit-
ment will be inflated to 90 participants to enable a 20%
participant attrition rate.
Participants
The inclusion criteria for the study are a medical diagno-
sis of CFS from the participant’s medical practitioner,
according to CDC criteria; an age range of 16 to 60 yr;
no diagnosed cardiorespiratory, endocrine, metabolic
condition or current musculoskeletal injury that would
make exercise participation hazardous; the ability to
communicate in English; provision of informed consent;
willingness to participate in three exercise sessions per
week. Participants will be recruited from the local com-
munity through advertisements at the Southern CrossUniversity campus and Health Clinic, local medical
clinics and hospitals, local newspapers, television and
radio media. Participants will be randomized via
computer-generated randomly permuted blocks strati-
fied by gender and age (< 40 years; > 40 years) into the
intervention groups and control group. A university em-
ployee not involved in exercise testing or delivery of the
intervention will prepare the randomization assign-
ments. Group assignment will be delivered to partici-
pants in sealed envelopes upon the completion of
baseline testing. Participants who have been randomized
into the control group will be offered a supervised 12-
week exercise program upon completion of the study.
Interventions
Exercise groups
Participants randomized to the exercise intervention
groups will engage in a 12-week exercise program
consisting of either intermittent exercise (IE) or graded
exercise (GE). The exercise sessions will be group-based
and conducted at the Southern Cross University Health
Clinic, three times per week. All sessions will be super-
vised by an accredited Exercise Physiologist (AEP) and
post-graduate clinical exercise physiology students. Each
exercise session will consist of a 5 minute gentle warm
up of unloaded cycling, followed by initially a 10 to 15
minute block of either steady state exercise (GE) or
intermittent exercise (IE) at an intensity pre-determined
from the baseline VO2peak cycle test for each participant.
Depending upon the symptom limits of the exercise, the
duration of the exercise block can be gradually increased
for each participant as tolerated to either a steady state
(constant effort) low-moderate intensity cycling period,
(50% VO2peak, RPE 3 [0–10 Borg Scale]) initially for 10 mi-
nutes (GE group) OR an intermittent exercise block of 1
minute of moderate intensity cycling (60% VO2peak, RPE
4–5) alternated with 1 minute of unloaded or very low in-
tensity/unloaded cycling (20-30% VO2peak, RPE 1–2), to-
talling 20 minutes. A cool down of 5 minutes unloaded
cycling plus stretching of main muscle groups for both
groups is also included in the exercise session.
During the 12 weeks of training, we aim to progress the
duration of GE towards 20 min, as tolerated by the partici-
pant, and to progress the IE participants towards intervals
of 2–3 min of moderate intensity cycling, alternated with
1 minute intervals of low intensity cycling, totalling 25–30
min duration. Resting heart rate, heart rate variability
(standard deviation of the normal to normal R-R intervals
and the root mean square of differences of successive R-R
intervals), resting blood pressure, RPE, (0–10 Borg Scale)
and fatigue levels will be recorded prior to, and after, each
exercise session. Participants will be asked to record any
changes, such as elevated or depressed mood, changes to
sleep patterns or general well-being, that they perceive to
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training.
Control group
Participants randomized to the control group will be
asked to follow the advice of their medical practitioner
(rest, maintaining activity for daily activities, [ADL]).
Control group participants will be advised not to engage
in any other physical activity, and will be offered a similar
12-week exercise program after completion of the current
study. All study participants will be asked to complete an
ADL diary to control for normal daily movements.
Outcome measures
All outcome measures will be collected at baseline
(Week 0) and after the exercise interventions (Week 13).
Trained research personnel blinded to the rando-
mization procedures will conduct the initial participant
screenings and baseline assessments, which include a full
medical history, resting heart rate, resting blood pressure
and anthropometry (height; weight; BMI; waist, hip and
limb girths), fatigue severity and wellness questionnaires.
The project outcome measures consist of a full cell count;
lymphocyte receptor flow cytometric assays; incremen-
tal cycling test (VO2peak, anaerobic threshold); spirom-
etry; Personal Well Being Index [33] and Fatigue Severity
Scale [34].
Measures of immune function
The baseline and post-study full blood count with
leukocyte differential will be performed by Northern
Pathology at Lismore Base Hospital. Blood samples
will be de-identified and numerically coded. Ten mL
of blood will also be drawn to provide for flow cyto-
metric assays of CD3+CD4+CD+135 (T helper), CD3+CD8+
(cytotoxic effector) lymphocytes, CD45+ (HLA marker),
CD3+CD19+ (B cells) and CD56+CD16+ Natural Killer
(NK) cells. The absolute concentration of these lym-
phocyte subsets will be measured by flow cytometer
(FACSCanto ll, BD Biosciences, Australia) using the BD
Multitest 6-colour direct immunofluorescence TBNK re-
agent and BD Trucount tubes (BD Biosciences, Australia)
and FACSDiva v4.1 software (BD Biosciences, Australia).
The method for stimulating and measuring CD4+
CD25+CD134+ expression in whole blood samples is de-
scribed by Zaunders et al., (2009) [35]. Briefly, sodium
heparin anti-coagulated whole blood (0.5 mL) will be
mixed with 0.5 mL RPMI-1640 (Sigma-Aldrich, Australia),
and will be stimulated by 5 μg/mL phytohemagglutinin
(PHA) (Sigma-Aldrich, Australia) for 48 hr at 37°C in a
5% CO2 incubator. After culture, 100 μL of sample will
be stained with the following conjugated fluorochromes
for 15 min at room temperature (CD3-FITC; CD4-Per-
CP; CD25-APC; CD134-PE, BD Biosciences, Australia),followed by washing in PBS (1 mL), resuspension in 0.5
mL of 0.5% paraformaldehyde (Sigma-Aldrich, Australia)
and then multi-parameter flow cytometric analysis.
In a separate assay, both CD3+CD8+ and NK lympho-
cytes can be stimulated in an anti-coagulated whole blood
sample (0.5 mL blood and 0.5 mL RPMI-1640) by using
phorbol-12-myristate-13-acetate (PMA) (2.5 μg/mL) and
ionomycin (0.5 μg/mL). The activation of CD3+CD8+ will
be assessed through the co-expression of CD38 in re-
sponse PMA and ionomycin following a 6 hr incubation
at 37°C in a 5% CO2 incubator. The cytotoxic response
of CD3+CD8+ will be measured with the expression of
LAMP-1 (CD107a) and LAMP-2 (107b) as positive
markers of degranulation (perforin-granzyme mediated
killing) plus the concurrent intracellular production of
IFN-γ [36]. NK lymphocytes will be also be stimulated
by PMA and ionomycin for 6 hr to measure the expres-
sion of CD107a as an indicator of cytotoxic activity and
degranulation [37]. After stimulation of CD3+CD8+ and
NK cells, washing of the cells in PBS and resuspension in
paraformaldehyde, receptors can be measured as follows:
CD3-Per-CP; CD8-APC-H7; CD38-PE-Cy7; CD107a-
APC; CD107b-FITC; CD16-PE; CD56-PE (BD Biosciences,
Australia). In each experiment, a negative control (no PHA
or PMA/ionomycin) will be included to control for spon-
taneous receptor expression or cytokine production.
Measures of aerobic capacity
Each participant will undergo an incremental test to vol-
itional exhaustion on a cycle ergometer (Lode Excalibur,
Holland). Peak VO2 (mL.kg
-1.min-1), VCO2, ventilation
(VE BTPS L min
-1), ventilatory equivalents (VE/VO2,VE/
VCO2) and respiratory exchange ratio (RER) will be
measured using open circuit spirometry (AEI, Australia),
and recorded every 15 s, with peak values determined
from the average of the two highest values attained over
two collection periods during the exercise test. The cri-
teria for attaining VO2peak are when (1) VO2 increases
by < 0.15 L. min-1 despite an increase in power, (2) heart
rate is within ten beats of age-predicted maximum,
(3) when RER ≥ 1.15 and (4) when RPE ≥ 8 on the
0–10 Borg Scale. However we also accept that symptom
limits (fatigue) may stop the exercise test before these cri-
teria are reached. Throughout each incremental exercise
test, heart rate and rhythm will be monitored from bipolar
leads in the CM5 position; blood pressure will be moni-
tored every 2 min with standard auscultation; power (W)
will be recorded every 60 s (Lode Excalibur, Groningen,
Holland). Anaerobic threshold will be determined from in-
cremental test results using the V slope method [38], a
computerized regression analysis of the slopes of the CO2
uptake (VCO2) vs. O2 uptake (VO2) plot, which detects
the beginning of the excess CO2 output generated from
the buffering of [H+], relative to oxygen uptake.
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RPE and fatigue will be recorded at rest and during the
incremental exercise test. Participants will be asked to
complete a linear pain scale (0 – 10) to indicate if they
have any muscle or joint stiffness or soreness prior to
the exercise test, immediately post-exercise and also 24
hours post-exercise test. RPE and pain scales will also be
completed at every training session to carefully monitor
symptoms. The Fatigue Severity Scale [34] and the
Chalder Fatigue Scale [39], both CFS-specific, will be ad-
ministered pre- and post-study to assess the severity and
nature of the fatigue, mental and physical.
Wellness indices
Quality of life and wellness will be assessed pre- and
post-study using the Personal Well Being Index, [33]
and the Revised Clinical Interview Schedule medical his-
tory [40].
Statistical analyses
Primary analysis will be via intention-to-treat with all pa-
tients included regardless of dropout or level of adherence.
Missing data will be imputed according to the maximum
likelihood expectation algorithm via the Statistical Package
for the Social Sciences (SPSS© Version 19.0). Physiological
and exercise test data will be presented as the mean ±
standard deviation, with confidence intervals used to ex-
press group differences. Changes between groups and the
time effect for each group will be determined by repeated
measures analysis of variance with a Bonferroni adjust-
ment for significant differences between groups. Cohen’s
Effect sizes and 90% confidence intervals will be calcu-
lated, to utilise a magnitude-based approach to inferences
[41], with the following descriptors applied: (1) Effect
size thresholds: <0.2 trivial, <0.6 small, <1.2 moder-
ate, <2.0 large, <4.0 very large, >4.0 extremely large, and
(2) Thresholds for assigning qualitative terms to chances
of substantial effects: <0.5%, almost certainly not; <5.0%,
very unlikely; <25%, unlikely; <75%, possible; >75%,
likely; >95%, very likely; >99.5%, almost certain. An effect
is unclear if its confidence interval includes both substan-
tial increases and decreases [41]. A p value of < 0.05 will
be considered indicative of statistical significance; clinical
significance will be interpreted in light of the meaningful-
ness and magnitude of the adaptations observed. Data
from linear pain scales will be recorded pre- and post-
study, and reported as frequencies of scores between 0
and 10. Data will then be analysed using ANOVA (group
and time effects). Data from wellness indices will be
recorded pre and post, combined into domains and a
representative total score from the time points analysed
using an ANOVA. Data (non parametric) from the Fa-
tigue scales, also measured at time points, will be collated
and analysed using a Kruskall-Wallis test.Discussion
The results of this study will contribute evidence to
best-practice for management of CFS. Findings from this
research could improve health outcomes by reducing fa-
tigue, increasing aerobic capacity, wellness and immune
responses. Desired research outcomes could also be ap-
plied to the management of other chronic health condi-
tions where fatigue is a contributing factor.
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